An epidemiological, observational, multicenter, cross-sectional, retrospective study on patients ≥ 18 years visited in the oncology services of the participating centers with diagnosis of primary thyroid cancer.
Study Type
OBSERVATIONAL
Enrollment
20
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona, Spain
RECRUITINGHystopathological characteristics of the tumor
Based on pathologist evaluation of biopsy including differentiated, medullar or anaplasic.
Time frame: Baseline
Situation of the tumor at first-diagnosis
Local tumor, locoregional tumor or metastatic disease.
Time frame: Baseline
Tumor-Node-Metastasis classification
Based on the AJCC (American Joint Committee on Cancer) 2018 TNM system: T for extent or size of the tumor, N for lymph nodes spread and M for metastasis.
Time frame: Baseline
Tumor Stage
From I to IV, based on the interpretation of the TNM classification and depending on the hystopathological characteristics of the tumor.
Time frame: Baseline
Patient situation at the end of treatment
Results of clinical evaluation of the disease including complete response, partial response, stable disease, progression of disease or death
Time frame: 12 months
Number of patients with BRAF mutation
Total patients with available results on BRAF status and proportion of patients with mutated BRAF or native BRAF.
Time frame: 12 months
Number of patients with RET mutation
Total patients with available results on RET status and proportion of patients with mutated RET or native RET.
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Number of patients with PI3K mutation
Total patients with available results on PI3K status and proportion of patients with mutated PI3K or native PI3K.
Time frame: 12 months
Number of patients with RAS mutation
Total patients with available results on RAS status and proportion of patients with mutated RAS or native RAS.
Time frame: 12 months
Number of patients with PAX8/PAR mutation
Total patients with available results on PAX8/PAR status and proportion of patients with mutated PAX8/PAR or native PAX8/PAR.
Time frame: 12 months
Number of patients with P53 mutation
Total patients with available results on P53 status and proportion of patients with mutated P53 or native P53.
Time frame: 12 months
Number of patients with PTEN mutation
Total patients with available results on PTEN status and proportion of patients with mutated PTEN or native PTEN.
Time frame: 12 months